Medicus Pharma (MDCX) grants director 50,000 stock options at $0.36
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Medicus Pharma Ltd. director Robert J. Ciaruffoli received a grant of stock options covering 50,000 common shares. The options have an exercise price of $0.36 per share, were granted on June 3, 2026, and are scheduled to vest quarterly in four equal installments over one year.
These options expire on June 3, 2031, and represent 50,000 derivative securities held by Ciaruffoli following this compensation-related award. The filing reports no open-market purchases or sales of Medicus Pharma common shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Ciaruffoli Robert J.
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 50,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (right to buy) — 50,000 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Option grant size: 50,000 options
Exercise price: $0.36 per share
Underlying shares: 50,000 common shares
+4 more
7 metrics
Option grant size
50,000 options
Stock Option (right to buy) granted to director
Exercise price
$0.36 per share
Conversion or exercise price of granted options
Underlying shares
50,000 common shares
Underlying security shares for the option grant
Post-grant derivative holdings
50,000 options
Total derivative securities following transaction
Grant date
June 3, 2026
Option grant date per footnote
Expiration date
June 3, 2031
Option expiration date
Vesting schedule
Quarterly over one year
Four equal installments per footnote
Key Terms
Stock Option (right to buy), Grant, award, or other acquisition, derivative securities, vest quarterly, +1 more
5 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
Grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
derivative securities financial
"derivativeTransactionCount: 1 derivative-type records"
Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.
vest quarterly financial
"The option is scheduled to vest quarterly in four equal installments"
expiration date financial
"expiration_date: 2031-06-03T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
What did Medicus Pharma (MDCX) report in this Form 4 filing?
Medicus Pharma reported that director Robert J. Ciaruffoli received a grant of stock options for 50,000 common shares. These options are a compensation-related award rather than an open-market share purchase or sale.
How many Medicus Pharma (MDCX) options were granted to Robert J. Ciaruffoli?
Robert J. Ciaruffoli was granted stock options covering 50,000 Medicus Pharma common shares. The option award increases his derivative holdings to 50,000 options, according to the post-transaction balance reported in the Form 4 filing.
What is the exercise price and expiry of the new Medicus Pharma (MDCX) options?
The granted stock options have an exercise price of $0.36 per Medicus Pharma common share and expire on June 3, 2031. This gives the director a multi-year right to purchase shares at that fixed price if the options vest.
How do the Medicus Pharma (MDCX) options granted to the director vest?
The options granted to director Robert J. Ciaruffoli are scheduled to vest quarterly in four equal installments over one year. This means 25% of the 50,000 options vest every quarter during the first year after the June 3, 2026 grant date.